Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.68 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | FEN1 | P39748 | 1/20 | 0.42 |
| ▸ | BUB1 | O43683 | 6/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 2/20 | 0.39 |
| ▸ | GSK3B | P49841 | 2/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.37 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.37 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6926709 | 0.81 | DYRK1A (0.68) | DYRK1AHSD17B10KDM4EBRD4MEN1 | |
| SCHEMBL6921110 | 0.81 | DYRK1A (1.00) | DYRK1ABUB1HSD17B10KDM4EGSK3B | |
| SCHEMBL7555285 | 0.80 | DYRK1A (0.49) | DYRK1ABRD4 | |
| SCHEMBL6695622 | 0.78 | GFER (0.63) | DYRK1APARP1HSD17B10KDM4EMEN1 | |
| SCHEMBL7283436 | 0.77 | CDC7 (0.52) | DYRK1AFEN1BUB1KDM4EGSK3A | |
| SCHEMBL1657531 | 0.74 | DYRK1A (0.58) | DYRK1AHSD17B10KDM4EMEN1KMT2A | |
| SCHEMBL23537356 | 0.73 | PARP1 (0.59) | DYRK1APARP1BUB1HSD17B10KDM4E | |
| SCHEMBL31027151 | 0.73 | DYRK1A (0.58) | DYRK1APARP1HSD17B10KDM4EMEN1 | |
| SCHEMBL29824193 | 0.73 | PARP1 (0.59) | DYRK1APARP1BUB1HSD17B10KDM4E | |
| SCHEMBL2220752 | 0.73 | DYRK1A (0.58) | DYRK1APARP1HSD17B10KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041684-B2 | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050043337-A1 | Selective beta3 adrenergic agonists | RITO CHRISTOPHER J (US) | 2005-02-24 | — | — | US | disclosed |
| US-6686372-B2 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2004-02-03 | — | — | US | disclosed |
| US-6514968-B1 | Treating a disease or condition in a mammal wherein the 5-HT receptor is implicated and modulation of 5-HT function is desired comprising | PHARMACIA & UPJOHN COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020165234-A1 | Selective B3 adrenergic agonists | CROWELL THOMAS A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6413991-B1 | ANTIDIABETIC AGENTS; DIETETICS | ELI LILLY AND COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-1210329-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-06-05 | — | — | EP | disclosed |
| EP-0827746-B1 | Carbazole analogues as selective beta3 adrenergic agonists | LILLY CO ELI (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001017963-A2 | AMINOALKOXY CARBAZOLES AND THEIR USE AS 5-HT LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-03-15 | — | — | WO | disclosed |
| US-6140352-A | FOR AGONIZING THE BETA 3 ADRENERGIC RECEPTOR TO TREAT TYPE II DIABETES AND OBESITY | ELI LILLY AND COMPANY (US) | 2000-10-31 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| EP-0353983-B1 | Lactam derivatives | GLAXO GROUP LTD (GB) | 1996-05-29 | — | — | EP | disclosed |
| EP-0345956-B1 | Tricyclic ketones | GLAXO GROUP LTD (GB) | 1994-03-16 | — | — | EP | disclosed |
| US-5202343-A | Treating anxiety, psychological disorders | GLAXO GROUP LIMITED (GB) | 1993-04-13 | — | — | US | disclosed |
| US-5183820-A | Useful for treatment of nausea, vomiting, irritable bowel syndrome and dyspepsia | GLAXO GROUP LIMITED (GB) | 1993-02-02 | — | — | US | disclosed |
| EP-0353983-A2 | Lactam derivatives | GLAXO GROUP LIMITED (GB) | 1990-02-07 | — | — | EP | disclosed |
| EP-0345956-A1 | Tricyclic ketones | GLAXO GROUP LIMITED (GB) | 1989-12-13 | — | — | EP | disclosed |
| US-4859662-A | Tetrahydro-imidazolylmethylcarbazolones and analogs thereof for treating 5-HT function disturbances | GLAXO GROUP LIMITED (GB) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043337-A1 | Selective beta3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | DYRK1A 1696/4885PARP1 4037/4885FEN1 4768/4885 |
| US-20020165234-A1 | Selective B3 adrenergic agonists | ADRB3, ADRB2, ADRB1 | DYRK1A 1650/4885PARP1 4053/4885FEN1 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.